Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Yili Group HK$6.25 billion acquisition of 34.33% of Ausnutria Dairy
We advised Yili on the acquisition of a controlling interest in Ausnutria
SVB Financial $2.25 billion concurrent offerings of notes and preferred stock
The company issued senior notes due 2026 and depositary shares representing Series D and Series E perpetual preferred stock
Synchrony Financial $750 million senior notes offering
The company issued investment-grade notes due 2031 in the SEC-registered offering
AngloGold Ashanti $750 million debt offering and cash tender offer
The company issued 3.375% notes due 2028 and offered to purchase its outstanding 5.125% notes due 2022
Bank of America $1.3 billion preferred stock offering
The company issued depositary shares, each representing an interest in its 4.25% non-cumulative preferred stock, Series QQ
Option Care Health $500 million notes offering
The company issued high-yield senior notes due 2029 in the Rule 144A / Regulation S offering
Kosmos Energy acquisition finance
We advised Kosmos on a multi-faceted acquisition financing
Banco Santander Chile $700 million Tier 1 capital notes
We advised Banco Santander Chile on the note sale
Enfusion $318.75 million IPO
We advised the underwriters on the IPO and NYSE listing
IVERIC bio $173.4 million stock offering
We advised the underwriters on the SEC-registered equity offering